Kamran Alam
Director of Finance/CFO at TAYSHA GENE THERAPIES, INC.
Net worth: 364 313 $ as of 2024-04-29
Kamran Alam active positions
| Companies | Position | Start | End |
|---|---|---|---|
| TAYSHA GENE THERAPIES, INC. | Director of Finance/CFO | 2020-07-31 | - |
| Corporate Secretary | - | - |
Career history of Kamran Alam
Former positions of Kamran Alam
| Companies | Position | Start | End |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Director of Finance/CFO | 2019-10-27 | 2020-06-30 |
| AVEXIS INC | Corporate Officer/Principal | 2016-03-31 | 2019-09-30 |
| APTINYX | Comptroller/Controller/Auditor | 2013-02-28 | 2016-03-31 |
Naurex, Inc.
 Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | Corporate Officer/Principal | - | - |
Training of Kamran Alam
| Kelley School of Business | Masters Business Admin |
| Stephen M. Ross School of Business | Undergraduate Degree |
Statistics
International
| United States | 8 |
Operational
| Director of Finance/CFO | 2 |
| Corporate Officer/Principal | 2 |
| Masters Business Admin | 1 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| ROCKET PHARMACEUTICALS, INC. | Health Technology |
| APTINYX | Health Technology |
| TAYSHA GENE THERAPIES, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
Naurex, Inc.
Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | Health Technology |
- Stock Market
- Insiders
- Kamran Alam
- Experience
